The DOI matches its Crossref record, with a small difference in title or year; 15 of the 15 references it cites were found in a registry or an index.
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Open accessAbstract
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure and cardiovascular death among patients with chronic heart failure and a left ventricular ejection fraction of 40% or less. Whether SGLT2 inhibitors are effective in patients with a higher left ventricular ejection fraction remains less certain. METHODS: We randomly assigned 6263 patients with heart failure and a left ventricular ejection fraction of more than 40% to receive dapagliflozin (at a dose of 10 mg once daily) or matching placebo, in addition to usual therapy. The primary outcome was a composite of worsening heart failure (which was defined as either an unplanned hospitalization for heart failure or an urgent visit for heart failure) or cardiovascular death, as assessed in a time-to-event analysis. RESULTS: Over a median of 2.3 years, the primary outcome occurred in 512 of 3131 patients (16.4%) in the dapagliflozin group and in 610 of 3132 patients (19.5%) in the placebo group (hazard ratio, 0.82; 95% confidence interval [CI], 0.73 to 0.92; P<0.001). Worsening heart failure occurred in 368 patients (11.8%) in the dapagliflozin group and in 455 patients (14.5%) in the placebo group (hazard ratio, 0.79; 95% CI, 0.69 to 0.91); cardiovascular death occurred in 231 patients (7.4%) and 261 patients (8.3%), respectively (hazard ratio, 0.88; 95% CI, 0.74 to 1.05). Total events and symptom burden were lower in the dapagliflozin group than in the placebo group. Results were similar among patients with a left ventricular ejection fraction of 60% or more and those with a left ventricular ejection fraction of less than 60%, and results were similar in prespecified subgroups, including patients with or without diabetes. The incidence of adverse events was similar in the two groups. CONCLUSIONS: Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure and a mildly reduced or preserved ejection fraction. (Funded by AstraZeneca; DELIVER ClinicalTrials.gov number, NCT03619213.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Risk of DKA is increased in persons using SGLT2is, especially in those being treated with insulin (especially if there has been a recent reduction in their insulin dose) and/or those with acute illnesses and prolonged fasting.1049,1050”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1049]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Large placebo-controlled trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of cardiovascular disease, and particularly hospitalisation for heart failure, in patients with type 2 diabetes at high risk of atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease.”
From Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Over the past decade, the use of medications that have been demonstrated to be effective in patients with HF with reduced ejection fraction (angiotensin receptor neprilysin inhibitors, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter 2 [SGLT2] inhibitors) has been evaluated in large-scale trials in patients with HF and mildly reduced ejection fraction and patients with HFpE”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the EMPEROR-Preserved trial (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction) and DELIVER trial (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure), SGLT2 inhibition reduced the risk of cardiovascular death and worsening HF events by 18% to 21%4,5 and improved KCCQ-CSS by 1.5 to 2.3 points”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“SGLT2 inhibitors reduce the incidence of heart failure and improve heart failurerelated outcomes, including hospitalization for heart failure and heart failure-related symptoms, in people with diabetes with preserved or reduced ejection fraction (250,(255)(256)(257)(298)(299)(300)(301)(302)(303)(304)(305)(306).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [302]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“This level was significantly lower than that in the STEP-HFpEF program (median, ≈470 pg/mL)36 and substantially lower than in other large-scale outcome trials in HFpEF (median 900–1400 pg/mL).3–6”
From Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity (2025) · cites this paper as [5]
The cited source says what the claim attributes to it.
In the citing paper
“A similar benefit for heart failure outcomes was seen in the Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial for dapagliflozin in people with mildly reduced or preserved ejection fraction (302).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [302]
The cited source says what the claim attributes to it.
In the citing paper
“A similar benefit for heart failure outcomes was seen in the Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trial for dapagliflozin in people with mildly reduced or preserved ejection fraction (290).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [290]
In the citing paper
“Sacubitril/valsartan, compared with valsartan, reduced the likelihood of the primary composite outcome of CV death and total HF hospitalization by 22% in those with an LVEF below or equal to the median of 57%.534”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [534]
In the citing paper
“Over the past decade, several large RCTs failed to achieve statistical significance with regard to effects on the primary outcomes in patients with HFpEF including: PEP-CHF (perindopril), CHARM-Preserved (candesartan), I-PRESERVE (irbesartan), TOPCAT (spironolactone), DIG Ancillary Trial (digoxin), and PARAGON-HF (sacubitril/valsartan). 477,[534][535][536][537][538]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [534]
In the citing paper
“DELIVER recruited 6263 patients with heart failure with mildly reduced or preserved (>40%) ejection fraction including 3109 patients without diabetes.”
In the citing paper
“There is good evidence to support the use of SGLT2 inhibitors as a foundational therapy to prevent cardiovascular death or hospitalisation for heart failure in patients with heart failure, irrespective of ejection fraction or history of previous diabetes.1, 2, 3, 4, 5”
In the citing paper
“Since 2021, two placebo-controlled SGLT2 inhibitor trials (EMPA-KIDNEY and DELIVER) have studied a large number of people without diabetes.”
In the citing paper
“Approximately 44% of patients randomized to either dapaglifl ozin or placebo had type 2 diabetes, and results were consistent regardless of the presence of type 2 diabetes.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [199]
In the citing paper
“The primary outcome of a composite of worsening heart failure, de fi ned as hospitalization or urgent visit for heart failure, or cardiovascular death was reduced by 18% in patients treated with dapagli fl ozin compared with placebo (HR 0.82 [95% CI 0.73 -0.92]; P < 0.001).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [199]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationDapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Self-citationEmpagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citation2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.012 · Cited by 2,862
Self-citationAngiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Anand, I. S., Ge, J., Lam, C. S. P., Maggioni, A. P., Martinez, F., Packer, M., Pfeffer, M. A., Pieske, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908655 · Cited by 2,430
Self-citationCategorical Data Analysis Using the SAS System
Ziegel, E. R., Stokes, M., Davis, C., & Koch, G. (1996) · Technometrics · doi:10.1080/00401706.1996.10484575 · Cited by 2,034
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials
Hicks, K. A., Mahaffey, K. W., Mehran, R., Nissen, S. E., Wiviott, S. D., Dunn, B., Solomon, S. D., Marler, J. R., Teerlink, J. R., Farb, A., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.033502 · Cited by 750
Self-citationSolomon, S. D., Claggett, B. L., Lewis, E. F., Desai, A. S., Anand, I. S., Sweitzer, N. K., O’Meara, E., Shah, S. J., McKinlay, S. M., Fleg, J. L., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv464 · Cited by 538
Self-citation
Cited by
Sorted by citations
Items 701–800 of 1,002
Cersosimo, A., Amore, L., Cimino, G., Arabia, G., Pagnesi, M., Inciardi, R. M., Adamo, M., Metra, M., & Vizzardi, E. (2025) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001733 · Cited by 12
Current Treatment of Heart Failure with Preserved Ejection Fraction
Riccardi, M., D’Elia, E., Lombardi, C., Savarese, G., Gori, M., Oliva, F. G., Volterrani, M., Senni, M., Metra, M., & Inciardi, R. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155406 · Cited by 13
SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction — The New Frontier
Aguiar‐Neves, I., Santos‐Ferreira, D., & Fontes‐Carvalho, R. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2401001 · Cited by 16
How to Use Natriuretic Peptides in Patients with Heart Failure with Non-Reduced Ejection Fraction?
Çelik, A. (2023) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2023.3297 · Cited by 12
Stompór, T. P., Adamczak, M., Kurnatowska, I., Naumnik, B., Nowicki, M. P., Tylicki, L., Winiarska, A., & Krajewska, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165184 · Cited by 15
Schmitt, A., Schupp, T., Reinhardt, M., Abel, N., Lau, F., Forner, J., Ayoub, M., Mashayekhi, K., Weiß, C., Akın, İ., et al. (2023) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuad139 · Cited by 13
Cardio‐renal‐metabolic disease in primary care setting
Ibrahim, M. A., Ba-Essa, E. M., Baker, J. C., Cahn, A., Ceriello, A., Cosentino, F., Davies, M. J., Eckel, R. H., Gaal, L. V., Gæde, P., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3755 · Cited by 13
Taheri, S. (2023) · World Journal of Nephrology · doi:10.5527/wjn.v12.i5.182 · Cited by 13
Cuthbert, J. J., Cleland, J. G. F., & Clark, A. J. L. (2024) · Current Heart Failure Reports · doi:10.1007/s11897-024-00644-2 · Cited by 14
Bhatt, A. S., Vaduganathan, M., Claggett, B. L., Kulac, I. J., Anand, I. S., Desai, A. S., Fang, J. C.-T., Hernandez, A. F., Jhund, P. S., Kosiborod, M., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032279 · Cited by 15
Self-citationProximal versus distal diuretics in congestive heart failure
Nardone, M., Sridhar, V. S., Yau, K., Odutayo, A., & Cherney, D. Z. I. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae058 · Cited by 14
Ishizu, K., Shirai, S., Isotani, A., Hayashi, M., Tabata, H., Ohno, N., Kakumoto, S., Andò, K., Yashima, F., Tada, N., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14773 · Cited by 12
Limonte, C. P., Lamprea-Montealegre, J. A., & Tuttle, K. R. (2024) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2024.151520 · Cited by 12
deFilippi, C. R., Shah, P. M., Shah, S. J., Alemayehu, W. G., Lam, C. S. P., Butler, J., Roessig, L., O’Connor, C. M., Westerhout, C. M., Armstrong, P. W., et al. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.011792 · Cited by 13
Self-citationRecent Advances in Understanding the Molecular Mechanisms of SGLT2 Inhibitors in Atrial Remodeling
Minciună, I., Tomoaia, R., Mihăilă, M.-D., Cismaru, G. L., Puiu, M., Roşu, R., Simu, G. R., Frîngu, F. I., Irimie, D. A., Caloian, B., et al. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46090571 · Cited by 16
Habel, N., Infeld, M. M., Lustgarten, D. L., & Meyer, M. (2024) · Heart Rhythm · doi:10.1016/j.hrthm.2024.08.064 · Cited by 15
Wu, C., Shah, B. R., Sharma, A., Sheng, Y., Liu, P. P., Kopp, A., Saskin, R., Edwards, J. D., & Swardfager, W. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3464 · Cited by 12
Spiazzi, B. F., Piccoli, G. F., Wayerbacher, L. F., Lubianca, J. P. N., Scalco, B. G., Scheffler, M. H., Fraga, B. L., Colpani, V., & Gerchman, F. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111933 · Cited by 13
Appropriate management of heart failure in older people with frailty
Woodford, H. J., McKenzie, D., & Pollock, L. (2024) · BMJ · doi:10.1136/bmj-2023-078188 · Cited by 14
Chuang, W.-L., Tsai, S. C., Yang, Y., Hsieh, T.-L., Lin, H.-J., Huang, Y., Tsai, F., & Chang, K. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03660-0 · Cited by 13
Shah, M. U., Roebuck, A., Srinivasan, B., Ward, J. K., Squires, P. E., Hills, C. E., & Lee, K. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1499681 · Cited by 15
Zhang, J., Chen, X., Lv, S., & Hao, Q. (2025) · PLoS ONE · doi:10.1371/journal.pone.0317295 · Cited by 12
Theodorakis, N., Nikolaou, M., & Krentz, A. J. (2025) · Biomolecules · doi:10.3390/biom15030373 · Cited by 12
Oliva, F. G., Orso, F., Colivicchi, F., Cipriani, M., Lenarda, A. D., Gabrielli, D., Gori, M., Gorini, M., Iacoviello, M., Lucci, D., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.02.019 · Cited by 17
Mu, Y., Geng, J., Liu, C., Jiang, S., Han, Y., Jiang, J., & Wang, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104847 · Cited by 13
Self-citationModern Approaches for the Treatment of Heart Failure: Recent Advances and Future Perspectives
Popa, I. P., Haba, M. Ș. C., Maranducă, M. A., Tănase, D. M., Șerban, D. N., Șerban, L., Iliescu, R., & Tudorancea, I. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091964 · Cited by 13
The Benefit of Sodium-Glucose Co-Transporter Inhibition in Heart Failure: The Role of the Kidney
Gronda, E., Vanoli, E., Iacoviello, M., Caldarola, P., Gabrielli, D., & Tavazzi, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911987 · Cited by 12
Pleiotropic effect of sodium-glucose cotransporter 2 inhibitors on blood pressure
Kao, T., & Huang, C. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1086672 · Cited by 13
Chen, H., Yang, Y., Meng, R., & Liu, X. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14297 · Cited by 13
Advances in contemporary medical management to treat patients with heart failure
Velez, M. (2023) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001021 · Cited by 13
Vaduganathan, M., Claggett, B. L., Jhund, P. S., Miao, Z. M., de Boer, R. A., Lam, C. S. P., Desai, A. S., Bengsston, O., McMurray, J. J. V., & Solomon, S. D. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.12.026 · Cited by 12
Self-citationBelančić, A., & Majanović, S. K. (2023) · Diabetology · doi:10.3390/diabetology4030022 · Cited by 12
Park, S. M., Lee, S. Y., Jung, M., Youn, J., Kim, D., Cho, J. Y., Cho, D., Hyun, J., Cho, H., Park, S., et al. (2023) · Korean Circulation Journal · doi:10.4070/kcj.2023.0114 · Cited by 11
Management of secondary mitral regurgitation: from drugs to devices
Barnes, C., Sharma, H. C., Gamble, J. H. P., & Dawkins, S. (2023) · Heart · doi:10.1136/heartjnl-2022-322001 · Cited by 14
Unmet Needs in the Treatment of Childhood Type 2 Diabetes: A Narrative Review
Tamborlane, W. V., & Shehadeh, N. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02642-7 · Cited by 12
Heart failure with improved ejection fraction: Beyond diagnosis to trajectory analysis
Pensa, A. V., Khan, S. S., Shah, R. V., & Wilcox, J. E. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.01.014 · Cited by 13
Szabo, B. A., Benson, L., Savarese, G., Hage, C., Fudim, M., Devore, A., Pitt, B., & Lund, L. H. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.02.021 · Cited by 14
How to Manage Beta-Blockade in Older Heart Failure Patients: A Scoping Review
Parrini, I., Lucà, F., Rao, C. M., Cacciatore, S., Riccio, C., Grimaldi, M., Gulizia, M. M., Oliva, F. G., & Andreotti, F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13072119 · Cited by 13
Radakrishnan, A., Agrawal, S., Singh, N., Barbieri, A., Shaw, L. J., Gulati, M., & Lala, A. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.100928 · Cited by 12
Ebong, I., Gill, A., Appiah, D., & Mauricio, R. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10528-9 · Cited by 12
Haider, S. H., Irfan, A., Sheikh, S. M., Larik, M. O., Raza, A., & Khabir, Y. (2025) · Clinical Medicine Insights Cardiology · doi:10.1177/11795468251347777 · Cited by 12
Gonzales-Uribe, A., Ruiz-Cortez, R., Silva, N. C., Olivero, L. J., Agarwal, R., Castillo, S. A., Garcia-Geng, A., Lyu, X., Mendoza‐Quispe, D., Becerra-Gonzales, V. G., et al. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02710-8 · Cited by 14
Multimodal, device-based therapeutic targeting of the cardiovascular autonomic nervous system
Paton, J. F. R., Żera, T., Vadigepalli, R., Herring, N., & Paterson, D. J. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01212-4 · Cited by 16
Gil, P., Gimeno-Orna, J. A., Padial, L. R., Muñiz, J., Barrios, V., Anguita, M. P., & Pérez, A. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02995-z · Cited by 11
Canto, E. D., Scheffer, M., Kortekaas, K. A., Driessen‐Waaijer, A., Paulus, W. J., & van Heerebeek, L. (2023) · Biomedicines · doi:10.3390/biomedicines11030867 · Cited by 11
Zhazykbayeva, S., Hassoun, R., Herwig, M., Budde, H., Kov́acs, Á., Mannherz, H. G., El‐Battrawy, I., Tóth, A., Schmidt, W. E., Mügge, A., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1157398 · Cited by 11
Pabón, M. A., Claggett, B. L., Wang, X., Miao, Z. M., Chatur, S., Bhatt, A. S., Vaduganathan, M., Fang, J. C., Desai, A. S., Jhund, P. S., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3001 · Cited by 12
Self-citationObesity as a risk factor in atrial fibrillation and heart failure
Jurica, J., Péč, M. J., Benko, J., Bolek, T., Galajda, P., Mokáň, M., & Samoš, M. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01332-z · Cited by 12
Pozzi, A., Cirelli, C., Merlo, A., Rea, F., Scangiuzzi, C., Tavano, E., Iorio, A., Kristensen, S. L., Wong, C., Iacovoni, A., et al. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10363-w · Cited by 13
Li, J., Zhu, C., Liang, J., Hu, J., Liu, H., Wang, Z., Guan, R., Chow, J., Yan, S., Li, L., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1303694 · Cited by 11
Iwakura, K., Onishi, T., Okamura, A., Koyama, Y., Tanaka, N., Okada, M., Fujii, K., Seo, M., Yamada, T., Yano, M., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-52101-8 · Cited by 11
Zou, X., Shi, Q., & Li, S. (2024) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12597 · Cited by 11
Davis, J. A., Booth, D., McEwan, P. C., Solomon, S. D., McMurray, J. J. V., de Boer, R. A., Colet, J. C., Bachus, E., & Chen, J. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3197 · Cited by 11
Self-citationMuta, Y., Kobayashi, K., Toyoda, M., Tone, A., Suzuki, D., Tsuriya, D., Machimura, H., Shimura, H., Takeda, H., Yokomizo, H., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1358573 · Cited by 11
Balestrieri, G., Limonta, R., Ponti, E., Merlo, A., Sciatti, E., D’Isa, S., Gori, M., Casu, G., Giannattasio, C., Senni, M., et al. (2024) · Cardiac failure review · doi:10.15420/cfr.2023.13 · Cited by 15
An Updated Review of the Management of Chronic Heart Failure in Patients with Chronic Kidney Disease
Tumelty, E. H., Chung, I., Hussain, S., Ali, M. A., Addada, H., & Banerjee, D. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2504144 · Cited by 11
Cuthbert, J. J., Soyiri, I. N., Lomax, S., Turgoose, J., Fuat, A., Cohen, J., & Clark, A. L. (2024) · Heart · doi:10.1136/heartjnl-2023-323577 · Cited by 11
Erez, Y., Ghantous, E., Shetrit, A., Zamanzadeh, R. S., Zahler, D., Granot, Y. N., Sapir, O. P. R., Perl, M. L., Banai, S., Topilsky, Y., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14776 · Cited by 11
Gagnon, L. R., Hazra, D., Perera, K., Wang, K., Kashyap, N., Sadasivan, C., Youngson, E. R. E., Chu, L. M., Dover, D. C., Kaul, P., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.04.007 · Cited by 11
Dixit, N. M., Truong, K. P., Vaduganathan, M., Ziaeian, B., & Fonarow, G. C. (2024) · JACC Heart Failure · doi:10.1016/j.jchf.2024.03.006 · Cited by 11
Self-citationBonacchi, G., Rossi, V. A., Garofalo, M., Mollace, R., Uccello, G., Pieragnoli, P., Checchi, L., Perrotta, L., Voltolini, L., Ricciardi, G., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12050981 · Cited by 14
Lassen, M. C. H., Ostrominski, J. W., Inzucchi, S. E., Claggett, B. L., Kulac, I. J., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Kosiborod, M., Lam, C. S. P., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3269 · Cited by 12
Self-citationNielsen, R. R., Pryds, K., Olesen, K. K. W., Mortensen, M. B., Gyldenkerne, C., Nielsen, J. C., Hindricks, G., Dagres, N., & Mæng, M. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033938 · Cited by 11
Zahir, D., Bonde, A. N., Fosbøl, E. L., Garred, C. H., Gislason, G., Elmegaard, M., Knigge, P., Torp-Pedersen, C. T., Andersson, C., Pfeffer, M. A., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14933 · Cited by 11
Self-citationOsataphan, N., Abdel-Qadir, H. M., Zebrowska, A. M., & Borowiec, A. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01577-8 · Cited by 11
Fano, M. D., Falorni, A., Malara, M., Porcellati, F., & Fanelli, C. G. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s466328 · Cited by 11
Hammersley, D. J., Mukhopadhyay, S., Chen, X., Jones, R. E., Ragavan, A., Javed, S., Rajabali, H., Androulakis, E. S., Curran, L., Mach, L., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3425 · Cited by 11
Kim, H., Lee, K. Y., Choo, E. H., Hwang, B., Kim, J.-J., Kim, C. J., Chang, K., Hong, Y. J., Kim, J. H., Ahn, Y., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.034870 · Cited by 13
Sidhu, G., & Rabkin, S. W. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13185533 · Cited by 11
Diagnostic and Therapeutic Practice for HFpEF Across Continents and Regions: An International Survey
Ingimarsdóttir, I. J., Vishram‐Nielsen, J. K. K., Einarsson, H., Goldfeder, S., Mewton, N., Barasa, A. L., Basic, C., Oerlemans, M. I. F. J., Niederseer, D., Shchendrygina, A., et al. (2024) · ESC Heart Failure · doi:10.1002/ehf2.15084 · Cited by 11
Bak, M., Ah, S., Jeon, K., Hong, D., Shin, H.-Y., Kim, D., & Choi, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-71231-7 · Cited by 11
Fuerlinger, A., Stockner, A., Sedej, S., & Abdellatif, M. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02566-8 · Cited by 12
Kidney Status and Events Preceding Death in Heart Failure: A Real-World Nationwide Study
Zahir, D., Garred, C. H., Carlson, N., Fosbøl, E. L., Elmegaard, M., Jhund, P. S., McMurray, J. J. V., Petrie, M. C., Køber, L., & Schou, M. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3631 · Cited by 11
Self-citationSevere Heart Failure and Treatment With Dapagliflozin Across the Ejection Fraction Spectrum
Inciardi, R. M., Lu, H. Y., Claggett, B. L., Desai, A. S., Jhund, P. S., Lam, C. S. P., Kosiborod, M., Inzucchi, S. E., Martínez, F. A., de Boer, R. A., et al. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2024.11.023 · Cited by 12
Self-citationFinerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model
McDowell, K., Docherty, K. F., Campbell, R. T., Henderson, A. D., Jhund, P. S., Claggett, B. L., Desai, A. S., Lay‐Flurrie, J., Hofmeister, L. H., Scalise, A. V., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.0025 · Cited by 11
Self-citationWhitman, J., Kozaily, E., Michos, E. D., Silverman, D. N., Fudim, M., Mentz, R. J., Tedford, R. J., & Rao, V. N. (2025) · Current Heart Failure Reports · doi:10.1007/s11897-025-00700-5 · Cited by 11
Management of Atrial Fibrillation in Elderly Patients: A Whole New Ballgame?
Parrini, I., Lucà, F., Rao, C. M., Ceravolo, R., Gelsomino, S., Ammendolea, C., Pezzi, L., Ingianni, N., Sindaco, D. D., Murrone, A., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14072328 · Cited by 12
Chen, J.-J., Hsu, C., Hung, C., Liang, C., Su, K., Carvalho, A. F., Stubbs, B., Chen, Y.-W., Chen, T., Lei, W., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18050735 · Cited by 13
Bauersachs, J. K., Kato, E. T., & Rangaswami, J. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15345 · Cited by 12
Yoon, M., Oh, J., Lee, C. J., & Kang, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-01537-7 · Cited by 11
Mohamed, A. A., Andersen, C. F., Christensen, D. M., Riis‐Vestergaard, L. D., Mohammad, M., Elmegaard, M., Binding, C., Torp-Pedersen, C., Biering‐Sørensen, T., Hansen, M. L., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02871-w · Cited by 11
Diuretics and Ultrafiltration in Heart Failure
Reis, T. D. A., Ronco, F., & Ostermann, M. (2023) · Cardiorenal Medicine · doi:10.1159/000529068 · Cited by 11
Palazzuoli, A., Correale, M., Iacoviello, M., & Gronda, E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020693 · Cited by 11
CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
Schnell, O., Battelino, T., Bergenstal, R. M., Birkenfeld, A. L., Ceriello, A., CHENG, A. Y. Y., Davies, M. J., Edelman, S. V., Forst, T. M., Giorgino, F., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01788-6 · Cited by 11
Self-citationEscobar, C., Palacios, B., Gonzalez, V., Gutiérrez, M., Duong, M., Chen, H., Justo, N., Cid-Ruzafa, J., Hernández, I., Hunt, P. R., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12062410 · Cited by 12
Sourij, C., Aziz, F., Tripolt, N. J., Siller-Matula, J. M., Pferschy, P. N., Kolesnik, E., Wallner, M., Eyileten, C., Postula, M. A., Oulhaj, A., et al. (2023) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2023.05.007 · Cited by 11
Wu, M., Ying, W., Chen, W., Kaizu, X., Song, M., & Lin, L. (2023) · Heart Failure Reviews · doi:10.1007/s10741-023-10338-x · Cited by 13
Management of type 2 diabetes in the new era
Liakos, A., Karagiannis, T., Avgerinos, I., Malandris, K., Τσάπας, Α., & Bekiari, E. (2023) · HORMONES · doi:10.1007/s42000-023-00488-w · Cited by 11
Rationale and Design of the ESC Heart Failure III Registry – Implementation and Discovery
Lund, L. H., Crespo‐Leiro, M. G., Laroche, C., García‐Pinilla, J. M., Bennis, A., Vataman, E., Polovina, M. M., Radovanović, S., Apostolovic, S. R., Ašanin, M., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3087 · Cited by 13
Abdelrahman, A. M., Awad, A. S., & Abdel‐Rahman, E. M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13040956 · Cited by 11
Kim, H. A., Kim, J. Y., Kim, Y. H., Lee, Y. T., & Park, P. W. (2024) · Scientific Reports · doi:10.1038/s41598-024-58853-7 · Cited by 11
Abdin, A., Kondo, T., Böhm, M., Jhund, P. S., Claggett, B. L., Vaduganathan, M., Hernandez, A. F., Lam, C. S. P., Inzucchi, S. E., Martínez, F. A., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3350 · Cited by 11
Self-citationCapece, U., Pavanello, C., Cinti, F., Leccisotti, L., Mezza, T., Ciccarelli, G., Moffa, S., Giuseppe, G. D., Soldovieri, L., Brunetti, M., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01491-5 · Cited by 13
DELIVERing Progress in Heart Failure with Preserved Ejection Fraction
Margulies, K. B. (2022) · New England Journal of Medicine · doi:10.1056/nejme2210177 · Cited by 11
Kani, R., Miyamoto, Y., Saito, T., Watanabe, A., Matsubara, K., Ejiri, K., Iwagami, M., Slipczuk, L., Hosseini, K., Fujisaki, T., et al. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133079 · Cited by 10
Efficacy and Safety of Heart Failure Treatment According to Frailty Status: A Systematic Review
Nijskens, C. M., Handoko, M. L., Remmelzwaal, S., Ziesemer, K. A., & Muller, M. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.125.042367 · Cited by 15
Using Artificial Intelligence to Adjudicate Major Adverse Cardiovascular Events in Clinical Trials
Marti-Castellote, P. M., Badrouchi, S., Claggett, B. L., Xu, D., Maddah, M., Khurshid, S. S., Vardeny, O., Lewis, E. F., Jhund, P. S., Desai, A. S., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.10.055 · Cited by 13
Self-citationBodea, O.-M., Serban, S., Craciun, M.-L., Mateescu, D.-M., Florescu, E., Mureșan, C.-O., Cotet, I.-G., Badalica-Petrescu, M., Munteanu, A. M., Velimirovici, D. E., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15010378 · Cited by 12
Yasmin, F., Hamza, M., Fahim, M. A. A., Asghar, M. S., Ullah, W., & Alraies, M. C. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102462 · Cited by 10
Parizad, R., Hatwal, J., Sadeghi, M. T., Brar, A. S., Desai, R., Batta, A., & Mohan, B. (2026) · Vascular Health and Risk Management · doi:10.2147/vhrm.s578698 · Cited by 13
Metadata
- Authors
- Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Desai, A. S., Jhund, P. S., Belohlavek, J., Chiang, C.-E., Borleffs, C. J. W., Comin-Colet, J., Dobreanu, D., Drozdz, J., Fang, J. C., Alcocer-Gamba, M. A., Al Habeeb, W., Han, Y., Cabrera Honorio, J. W., Janssens, S. P., Katova, T., Kitakaze, M., Merkely, B., O’Meara, E., Saraiva, J. F. K., Tereshchenko, S. N., Thierer, J., Vaduganathan, M., Vardeny, O., Verma, S., Pham, V. N., Wilderäng, U., Zaozerska, N., Bachus, E., Lindholm, D., Petersson, M., & Langkilde, A. M.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston (S.D.S., B.C., A.S.D., M.V.); the British Heart Foundation Glasgow Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, United Kingdom (J.J.V.M., P.S.J.); the Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen (R.A.B., C.S.P.L.), and Haga Teaching Hospital, the Hague (C.J.W.B.) — both in the Netherlands; the University of Wisconsin, Madison (D. DeMets); Duke University Medical Center, Durham, NC (A.F.H.); Yale School of Medicine, New Haven, CT (S.E.I.); Saint Luke’s Mid America Heart Institute, University of Missouri, Kansas City, Kansas City (M.N.K.); National Heart Center Singapore and Duke–National University of Singapore, Singapore (C.S.P.L.); National University of Cordoba, Cordoba (F.M.), and Jefe de Unidad de Insuficiencia Cardíaca, Centro de Educación Médica e Investigaciones Clínicas Norbert...
- Northwestern University (US)
- Semmelweis University (HU)
- ORCID
- Solomon, Scott D.
- McMurray, John J.V.
- Claggett, Brian
- de Boer, Rudolf A.
- DeMets, David
- Hernandez, Adrian F.
- Inzucchi, Silvio E.
- Kosiborod, Mikhail N.
- Lam, Carolyn S.P.
- Shah, Sanjiv J.
- Desai, Akshay S.
- Jhund, Pardeep S.
- Chiang, Chern-En
- Dobreanu, Dan
- Fang, James C.
- Alcocer-Gamba, Marco Antonio
- Han, Yaling
- Janssens, Stefan P.
- Kitakaze, Masafumi
- Merkely, Béla
- O’Meara, Eileen
- Tereshchenko, Sergey N.
- Thierer, Jorge
- Vaduganathan, Muthiah
- Vardeny, Orly
- Verma, Subodh
- Pham, Vinh Nguyen
- Wilderäng, Ulrica
- Bachus, Erasmus
- Lindholm, Daniel
- Petersson, Magnus
- Langkilde, Anna Maria
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-09-22
- Volume
- 387
- Issue
- 12
- Pages
- 1089-1098
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4293354639
- Cited by
- 2,884
- References
- 15
- Citations by year
- 2026: 635 · 2025: 716 · 2024: 714 · 2023: 673 · 2022: 139
- FWCI
- 390.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, cc-by-sa)
- Lirias (KU Leuven) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- AstraZeneca
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- dapagliflozin, SGLT2 inhibitors, heart failure, preserved ejection fraction, mildly reduced ejection fraction, heart failure hospitalization, cardiovascular mortality, left ventricular ejection fraction
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Diabetes Mellitus, Type 2, Glucosides, Heart Failure, Humans, Stroke Volume, Ventricular Function, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
